Escitalopram
- Generic Name
- Escitalopram
- Brand Names
- Cipralex, Lexapro
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21FN2O
- CAS Number
- 128196-01-0
- Unique Ingredient Identifier
- 4O4S742ANY
- Background
Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with...
- Indication
Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disor...
- Associated Conditions
- Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)
- Associated Therapies
- -
The Effect of Cipralex on Quality of Life, Adrenal Activity Glucose Metabolism, Physical and Mental Health in PCOS
- First Posted Date
- 2013-10-11
- Last Posted Date
- 2016-05-09
- Lead Sponsor
- Odense University Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT01961180
- Locations
- 🇩🇰
Department of Endocrinology, Odense University Hospital, Odense, Denmark
Mechanisms of Antidepressant Non-Response in Late-Life Depression
- Conditions
- Interventions
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2020-07-02
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 138
- Registration Number
- NCT01931202
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Brain Aging and Treatment Response in Geriatric Depression
- Conditions
- Interventions
- First Posted Date
- 2013-07-17
- Last Posted Date
- 2019-10-15
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 115
- Registration Number
- NCT01902004
- Locations
- 🇺🇸
UCLA Semel Institute - Neuropsychiatric Institute (NPI), Los Angeles, California, United States
Interpersonal Psychotherapy for Treatment Resistant Depression
- Conditions
- Interventions
- Other: IPT+ antidepressant drugsDrug: fluoxetineDrug: sertralineDrug: paroxetineDrug: CitalopramDrug: escitalopramDrug: fluvoxamineDrug: VenlafaxineDrug: DuloxetineDrug: BupropionDrug: LithiumDrug: RisperidoneDrug: tranylcypromineDrug: ImipramineDrug: amitriptylineDrug: ClomipramineDrug: nortriptylineDrug: trazodoneDrug: MirtazapineDrug: sulpiride
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2013-07-11
- Lead Sponsor
- Hospital de Clinicas de Porto Alegre
- Target Recruit Count
- 74
- Registration Number
- NCT01896349
- Locations
- 🇧🇷
Federal University of Rio Grande do Sul / Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil
Clinical Trial to Investigate the Effect on Corrected QT Interval Prolongation by Psychotropic Drugs
- Conditions
- Interventions
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2014-06-03
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT01871701
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Gyounggi, Korea, Republic of
A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety Symptom
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- Xian-Janssen Pharmaceutical Ltd.
- Target Recruit Count
- 261
- Registration Number
- NCT01870843
Escitalopram for the Treatment of Depression in Alzheimer's Disease
- First Posted Date
- 2013-04-26
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Konkuk University Medical Center
- Target Recruit Count
- 84
- Registration Number
- NCT01841125
- Locations
- 🇰🇷
MedicalExcellence, Seoul, Secho-gu banpo-dong, Korea, Republic of
A Safety and Efficacy Study of Escitalopram on Acute Treatment of Severe Depression
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2014-01-03
- Lead Sponsor
- Xian-Janssen Pharmaceutical Ltd.
- Target Recruit Count
- 225
- Registration Number
- NCT01814085
An Efficacy and Safety Study of Escitalopram Long-Term Treatment in Major Depressive Disorder With Associated Anxiety Symptoms
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2017-10-02
- Lead Sponsor
- Xian-Janssen Pharmaceutical Ltd.
- Target Recruit Count
- 318
- Registration Number
- NCT01814098
A Trial Examining the Efficacy of Escitalopram Oxalate Upon Depressive Symptoms and Fatigue in HIV Seropositive Women
- First Posted Date
- 2013-02-22
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Duke University
- Target Recruit Count
- 5
- Registration Number
- NCT01797380
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.